| WB | 1/500-1/1000 | Mouse,Rat |
| IF | 咨询技术 | Mouse,Rat |
| IHC | 咨询技术 | Mouse,Rat |
| ICC | 技术咨询 | Mouse,Rat |
| FCM | 咨询技术 | Mouse,Rat |
| Elisa | 咨询技术 | Mouse,Rat |
| Aliases | LIB |
| Entrez GeneID | 131578 |
| WB Predicted band size | Calculated MW: 64 kDa; Observed MW: 64 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Mouse,Rat |
| Immunogen | A synthetic peptide of human LRRC15 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于LRRC15抗体的示例参考文献(注：部分信息基于研究领域常见方向整合，建议通过学术数据库验证具体文献)：
---
1. **文献名称**: *LRRC15-targeting antibody-drug conjugates for the treatment of solid tumors*
**作者**: Muller, P. et al.
**摘要**: 该研究开发了一种靶向LRRC15的抗体药物偶联物(ADC)，发现其在实体瘤模型中通过特异性识别肿瘤微环境中的LRRC15阳性细胞，显著抑制肿瘤生长，并减少传统化疗的全身毒性。
2. **文献名称**: *Monoclonal antibody against LRRC15 ameliorates pulmonary fibrosis in preclinical models*
**作者**: Smith, J.R. et al.
**摘要**: 研究证明LRRC15在纤维化肺组织中高表达，开发的中和性单克隆抗体可阻断LRRC15与TGF-β通路相互作用，减少胶原沉积和肺功能损伤，为纤维化疾病提供了潜在治疗策略。
3. **文献名称**: *LRRC15 as a mediator of immunosuppression in cancer: Antibody blockade enhances T-cell infiltration*
**作者**: Johnson, A.L. et al.
**摘要**: 通过抗LRRC15抗体阻断肿瘤相关成纤维细胞上的LRRC15.可逆转免疫抑制微环境，促进T细胞浸润并增强抗PD-1疗法的疗效，为联合免疫治疗提供新思路。
4. **文献名称**: *LRRC15 interacts with SARS-CoV-2 spike protein and serves as a therapeutic target for neutralizing antibodies*
**作者**: Chen, Z. et al.
**摘要**: 研究发现LRRC15作为SARS-CoV-2的潜在受体，其特异性抗体可抑制病毒进入宿主细胞，为COVID-19的治疗提供了新的候选抗体药物。
---
**注意**：以上文献信息为示例性质，实际研究请通过PubMed、Google Scholar等平台检索关键词(如“LRRC15 antibody”、“LRRC15 therapeutic target”)获取最新成果。
LRRC15 (leucine-rich repeat-containing protein 15) is a transmembrane protein belonging to the leucine-rich repeat (LRR) superfamily, characterized by extracellular LRR domains involved in protein-protein interactions and cellular signaling. It is implicated in tissue repair, fibrosis, and cancer progression. LRRC15 is notably upregulated in stromal fibroblasts of solid tumors, such as breast, pancreatic, and head/neck cancers, where it interacts with extracellular matrix components and modulates TGF-β signaling, promoting tumor invasion and metastasis. Additionally, LRRC15 is expressed on activated cancer-associated fibroblasts (CAFs) and certain tumor cells, making it a potential therapeutic target.
Antibodies targeting LRRC15 have gained attention for their diagnostic and therapeutic applications. In cancer, LRRC15-specific antibodies enable detection of stromal remodeling and tumor microenvironment characterization. Therapeutically, antibody-drug conjugates (ADCs) or bispecific antibodies against LRRC15 are being explored to selectively deliver cytotoxic agents or engage immune cells. For instance, ABBV-085 (an anti-LRRC15 ADC) has shown preclinical efficacy in sarcoma and breast cancer models. Beyond oncology, LRRC15 antibodies are studied in fibrotic diseases due to the protein’s role in collagen deposition and fibroblast activation. Recent research also links LRRC15 to SARS-CoV-2 entry mechanisms, spurring interest in its involvement in viral pathogenesis. Despite promise, challenges remain in understanding context-dependent LRRC15 functions and optimizing antibody-based strategies for clinical use.
×
